Associated Genetic Biomarkers
SLC29A1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains SLC29A1 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with SLC29A1 status in the inclusion eligibility criteria most commonly target breast carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are SLC29A1 Amplification and SLC29A1 Overexpression .
Capecitabine and targeted therapy agent are the most frequent therapies in trials with SLC29A1 as an inclusion criteria .
Significance of SLC29A1 in Diseases
Breast Carcinoma +
SLC29A1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLC29A1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.